CureVac ( (CVAC) ) has issued an update. CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...